首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study
【2h】

A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study

机译:混合西罗莫司洗脱支架与生物可吸收聚合物支架与依维莫司洗脱支架与持久性聚合物支架在全冠状动脉闭塞中的随机多中心比较:闭塞性天然冠状动脉初次支架的基本原理和设计IV

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundPercutaneous recanalization of total coronary occlusion (TCO) was historically hampered by high rates of restenosis and reocclusions. The PRISON II trial demonstrated a significant restenosis reduction in patients treated with sirolimus-eluting stents compared with bare metal stents for TCO. Similar reductions in restenosis were observed with the second-generation zotarolimus-eluting stent and everolimus-eluting stent. Despite favorable anti-restenotic efficacy, safety concerns evolved after identifying an increased rate of very late stent thrombosis (VLST) with drug-eluting stents (DES) for the treatment of TCO. Late malapposition caused by hypersensitivity reactions and chronic inflammation was suggested as a probable cause of these VLST. New DES with bioresorbable polymer coatings were developed to address these safety concerns. No randomized trials have evaluated the efficacy and safety of the new-generation DES with bioresorbable polymers in patients treated for TCO.
机译:背景技术历史上,高比例的再狭窄和再闭塞阻碍了全冠状动脉闭塞(TCO)的经皮再通。 PRISON II试验表明,与TCO裸金属支架相比,西罗莫司洗脱支架治疗的患者的再狭窄明显减少。用第二代佐他莫司洗脱支架和依维莫司洗脱支架观察到再狭窄的相似减少。尽管具有良好的抗再狭窄功效,但使用药物洗脱支架(DES)来治疗TCO的非常晚的支架血栓形成(VLST)发生率增加后,安全性仍引起关注。提示由超敏反应和慢性炎症引起的后期不良反应是这些VLST的可能原因。为了解决这些安全问题,开发了具有生物可吸收聚合物涂层的新型DES。尚无随机试验评估具有生物可吸收性聚合物的新一代DES在TCO治疗患者中的疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号